ACADIA Pharmaceuticals Inc. (ACAD)

Market Cap	3.70B
Revenue (ttm)	996.28M
Net Income (ttm)	228.88M
Shares Out	167.36M
EPS (ttm)	1.37
PE Ratio	16.77
Forward PE	42.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,738,146
Open	22.18
Previous Close	22.21
Day's Range	21.72 - 22.56
52-Week Range	13.40 - 25.23
Beta	0.65
Analysts	Buy
Price Target	27.89 (+26.09%)
Earnings Date	Aug 5, 2025

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2004
• Employees: 654
• Stock Exchange: NASDAQ
• Ticker Symbol: ACAD
• Website: https://www.acadia.com

Analyst Forecast

According to 19 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $27.89, which is an increase of 26.09% from the latest price.

Price Target

$27.89

(26.09% upside)

Analyst Consensus: Buy